Peptide ·Strong evidence ·Reviewed May 2026
Tesamorelin is a stabilized GHRH analog that is FDA-approved as prescription Egrifta products for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not FDA-approved for general weight loss, bodybuilding, anti-aging, or non-HIV body recomposition, and those uses have limited evidence and meaningful risks. Safety concerns include elevated IGF-1, glucose intolerance, edema, arthralgia, hypersensitivity, pregnancy contraindication, and avoidance in active malignancy or disrupted hypothalamic-pituitary axis.
The bottom line
Evidence rating strong. Most-documented uses: fda-approved reduction of excess abdominal fat in hiv-associated lipodystrophy, raises endogenous gh and igf-1 under prescription monitoring, may reduce liver fat in selected hiv studies. 3 sources indexed (2012–2025), with 3 interaction records on file.
Core mechanism
Tesamorelin activates pituitary GHRH receptors to increase pulsatile endogenous GH release and downstream IGF-1. In HIV-associated lipodystrophy trials this reduced visceral adipose tissue without being a general weight-loss drug. GH and IGF-1 effects can also worsen glucose tolerance, fluid retention, carpal tunnel symptoms, and theoretical tumor-growth risk.1,2
Subcutaneous injection only. Egrifta formulations are not substitutable and have specific reconstitution instructions.
Ranked by evidence and value.
Real-world pricing across three quality tiers. Assumes FDA-approved prescription injection.
Prescription drug cost and insurance coverage vary widely; non-prescription products are not appropriate substitutes. Updated 2026-06-04.
Dose: Use FDA-approved product label dosing2
Timing: Once daily subcutaneous injection per label
Continue only with documented benefit and monitoring.
Dose: No FDA-approved dose
Timing: Not applicable
Label states it is not indicated for weight loss management.
Dose: No FDA-approved dose
Timing: Not applicable
Benefits outside HIV lipodystrophy are not established and risks remain.
What to test, the optimal window inside the conventional range, and how long a response takes.
Expected to increase with treatment; persistent high values may require discontinuation or reassessment.2
FDA labeling recommends IGF-1 monitoring during therapy.
May worsen glucose tolerance in susceptible users.3
Monitor fasting glucose and A1c before and during therapy.
Where this appears in the symptom-to-supplement map, ranked by relevance.
Prescription GHRH analog reduces visceral adipose tissue in the approved HIV lipodystrophy population.1,2
Requires clinician diagnosis and monitoring.
Raises GH and IGF-1, but use depends on approved indication and endocrine context.3
Low IGF-1 requires endocrine evaluation.
Evidence outside HIV-associated lipodystrophy is insufficient for routine use.2,1
Not indicated for general weight loss.
Berberine may lower glucose while tesamorelin can worsen glucose tolerance, complicating monitoring.
Recommendation: Do not use supplements to offset tesamorelin-related dysglycemia without clinician oversight; monitor glucose and A1c.
Alpha-lipoic acid can affect glucose handling while tesamorelin requires glucose monitoring.
Recommendation: Track glucose trends and report hypoglycemia or hyperglycemia symptoms.
Creatine can increase body water and scale weight, while tesamorelin can cause edema or fluid-related symptoms.
Recommendation: Differentiate expected creatine water weight from new edema, numbness, carpal tunnel symptoms, or joint pain.
Numbered references. Citations throughout the page link here.
Tesamorelin reduced visceral adipose tissue and liver fat over 6 months in HIV-infected patients with abdominal fat accumulation.
Review summarized phase 3 trials showing reduced visceral adipose tissue and waist circumference after 26 weeks.
Label states indication, dosing, contraindications, IGF-1 and glucose warnings, and limitations of use.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
